Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis [2]

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 7, 2007, Pages 771-

  Baek, William S ^a   Bashey, Asad ^b   Sheean, Geoffrey L ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATINE KINASE MM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; STEROID;

ADULT; CASE REPORT; DRUG EFFICACY; HUMAN; JAUNDICE; LETTER; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

EID: 34347264888     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.093567     Document Type: Letter

References (5)

1. Monson NL, Cravens PD, Frohman EM, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005;62:258-64.
2. Hain B, Jordan K, Deschauer M, et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006;33:575-80.
3. Zaja F, Russo D, Fuga G, et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062-3.
4. Takagi K, Yoshida A, Iwasaki H, et al. Anti-CD20 antibody (rituximab) therapy in a myasthenia gravis patient with follicular lymphoma. Ann Hematol 2005;84:548-50.
5. Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am J Hematol 2004;77:196-7.